

# Antonio Sacco

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8591761/antonio-sacco-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

4,828  
citations

36  
h-index

69  
g-index

150  
ext. papers

5,525  
ext. citations

4.1  
avg, IF

4.59  
L-index

#	Paper	IF	Citations
148	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. <i>Science Advances</i> , <b>2022</b> , 8, eabl4644	14.3	4
147	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , <b>2021</b> , 2, 338-353	7	1
146	Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. <i>Blood</i> , <b>2021</b> , 138, 1705-1720	2.2	3
145	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , <b>2021</b> , 138, 1535-1539	2.2	7
144	MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
143	Progression signature underlies clonal evolution and dissemination of multiple myeloma. <i>Blood</i> , <b>2021</b> , 137, 2360-2372	2.2	9
142	Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. <i>Blood</i> , <b>2021</b> , 137, 2495-2508	2.2	1
141	FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress. <i>Cancer Research</i> , <b>2020</b> , 80, 2340-2354	10.1	18
140	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1198-1208	2.2	40
139	Vascular and Stromal Contributions to Tumor Bone-Homing: Focus on Multiple Myeloma <b>2020</b> , 236-242		
138	Epigenetic Aberrations in Multiple Myeloma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
137	Circulating microRNAs and Their Role in Multiple Myeloma. <i>Non-coding RNA</i> , <b>2019</b> , 5,	7.1	5
136	Targeting transcription factors in multiple myeloma: evolving therapeutic strategies. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 445-462	5.9	10
135	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. <i>Blood Advances</i> , <b>2019</b> , 3, 995-1002	7.8	5
134	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1454-1463	6.1	49
133	Platelets Enhance Multiple Myeloma Progression via IL-1 $\beta$ upregulation. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2430-2439	12.9	26
132	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2487-2499	15.9	48

131	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. <i>Blood</i> , <b>2018</b> , 132, 55-55	2.2	
130	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204589	3.7	13
129	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , <b>2017</b> , 129, 2429-2436	2.2	161
128	A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E138-E145	7.1	2
127	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , <b>2017</b> , 19, 218-224	6.6	67
126	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. <i>Current Osteoporosis Reports</i> , <b>2017</b> , 15, 499-506	5.4	18
125	Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. <i>Endocrinology</i> , <b>2017</b> , 158, 3369-3385	4.8	36
124	Molecular Pathways in Growth and Survival: Epigenomics <b>2017</b> , 67-71		1
123	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. <i>Oncotarget</i> , <b>2017</b> , 8, 35435-35444	3.3	3
122	Targeting vasculogenesis to prevent progression in multiple myeloma. <i>Leukemia</i> , <b>2016</b> , 30, 1103-15	10.7	37
121	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. <i>Cancer Research</i> , <b>2016</b> , 76, 463-71	10.1	31
120	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 1137-1137	2.2	2
119	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 197-197	2.2	7
118	Exosomes in Tumor Angiogenesis. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1464, 25-34	1.4	24
117	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 237-237	2.2	
116	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. <i>Blood</i> , <b>2016</b> , 128, 4483-4483	2.2	
115	Profiling of Circulating Exosomes in Patients with Waldenström Macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 2940-2940	2.2	
114	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , <b>2016</b> , 127, 2598-606	2.2	16

113	Epigenomics in Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2016</b> , 29, 156-160	4.2	1
112	Epigenetics in Multiple Myeloma. <i>Cancer Treatment and Research</i> , <b>2016</b> , 169, 35-49	3.5	6
111	Metabolic signature identifies novel targets for drug resistance in multiple myeloma. <i>Cancer Research</i> , <b>2015</b> , 75, 2071-82	10.1	112
110	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. <i>Leukemia</i> , <b>2015</b> , 29, 2338-46	10.7	27
109	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , <b>2015</b> , 12, 622-35	10.6	94
108	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 23-23	2.2	10
107	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 502-502	2.2	4
106	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 1755-1755	2.2	
105	A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish. <i>Blood</i> , <b>2015</b> , 126, 915-915	2.2	
104	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 1770-1770		
103	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 1793-1793	2.2	0
102	Engineered nanomedicine for myeloma and bone microenvironment targeting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 10287-92	11.5	204
101	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. <i>Blood</i> , <b>2014</b> , 124, 1765-76	2.2	80
100	Pyk2 promotes tumor progression in multiple myeloma. <i>Blood</i> , <b>2014</b> , 124, 2675-86	2.2	48
99	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. <i>Blood</i> , <b>2014</b> , 123, 4120-31	2.2	150
98	Global epigenetic regulation of microRNAs in multiple myeloma. <i>PLoS ONE</i> , <b>2014</b> , 9, e110973	3.7	28
97	The role of miRNAs in plasma cell dyscrasias. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , <b>2014</b> , 2, 165-73	2.9	3
96	Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. <i>Blood Cancer Journal</i> , <b>2014</b> , 4, e204	7	9

95	SDF-1 inhibition targets the bone marrow niche for cancer therapy. <i>Cell Reports</i> , <b>2014</b> , 9, 118-128	10.6	93
94	Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 1030-6	7.1	13
93	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. <i>Blood</i> , <b>2014</b> , 124, 3250-9	2.2	98
92	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 3431-3431	2.2	4
91	Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination. <i>Blood</i> , <b>2014</b> , 124, 4709-4709	2.2	1
90	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. <i>Blood</i> , <b>2014</b> , 124, 2051-2051	2.2	
89	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. <i>Blood</i> , <b>2014</b> , 124, 3430-3430	2.2	
88	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. <i>Blood</i> , <b>2014</b> , 124, 4719-4719	2.2	
87	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. <i>Blood</i> , <b>2014</b> , 124, 2101-2101	2.2	
86	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. <i>Blood</i> , <b>2014</b> , 124, 2056-2056	2.2	
85	microRNA aberrations in Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 205-7	2	14
84	BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 1542-55	15.9	555
83	Candidate genes of Waldenström's macroglobulinemia: current evidence and research. <i>The Application of Clinical Genetics</i> , <b>2013</b> , 6, 33-42	3.1	4
82	Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma. <i>PLoS ONE</i> , <b>2013</b> , 8, e66982	3.7	12
81	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. <i>Blood</i> , <b>2013</b> , 122, 272-272	2.2	3
80	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. <i>Blood</i> , <b>2013</b> , 122, 273-273	2.2	2
79	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. <i>Blood</i> , <b>2013</b> , 122, 680-680	2.2	3
78	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/βCatenin Signaling Pathway. <i>Blood</i> , <b>2013</b> , 122, 3094-3094	2.2	

77	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 121-121	2.2	
76	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. <i>Blood</i> , <b>2013</b> , 122, 3086-3086	2.2	
75	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 3159-3159	2.2	
74	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. <i>Blood</i> , <b>2013</b> , 122, 275-275	2.2	
73	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 3751-3751	2.2	
72	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. <i>Blood</i> , <b>2013</b> , 122, 3093-3093	2.2	
71	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. <i>Blood</i> , <b>2012</b> , 119, 1468-78	2.2	84
70	Targeting NAD <sup>+</sup> salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. <i>Blood</i> , <b>2012</b> , 120, 3519-29	2.2	100
69	LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. <i>Blood</i> , <b>2012</b> , 120, 1678-86	2.2	116
68	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. <i>Blood</i> , <b>2012</b> , 119, 5782-94	2.2	234
67	Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 91-104	12.9	25
66	Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 6609-22	12.9	11
65	Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients. <i>Blood</i> , <b>2012</b> , 120, 3975-3975	2.2	1
64	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. <i>Blood</i> , <b>2012</b> , 120, 440-440	2.2	1
63	CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells. <i>Blood</i> , <b>2012</b> , 120, 4009-4009	2.2	
62	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 3944-3944	2.2	
61	Let-7 MicroRNA Family Members Regulate Cell Proliferation in Multiple Myeloma. <i>Blood</i> , <b>2012</b> , 120, 570-570		
60	Targeting the bone marrow in Waldenstrom macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11 Suppl 1, S65-9	2	5

59	Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 109-11	2	2
58	The bone marrow niche in Waldenström's macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 118-20	2	2
57	Anti-angiogenic therapies in the treatment of Waldenström's Macroglobulinemia. <i>Current Cancer Drug Targets</i> , <b>2011</b> , 11, 1025-9	2.8	1
56	Defining the role of TORC1/2 in multiple myeloma. <i>Blood</i> , <b>2011</b> , 118, 6860-70	2.2	64
55	The bone marrow microenvironment in waldenstrom macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , <b>2011</b> , 2, 267-72	5.7	2
54	Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1753-64	12.9	38
53	FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4389-99	12.9	17
52	The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 1844-1844	2.2	2
51	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 625-625	2.2	2
50	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. <i>Blood</i> , <b>2011</b> , 118, 471-471	2.2	
49	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 1804-1804	2.2	
48	L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib. <i>Blood</i> , <b>2011</b> , 118, 887-887	2.2	
47	Role of TORC1 and TORC2 in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 1815-1815	2.2	
46	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia,. <i>Blood</i> , <b>2011</b> , 118, 3669-3669	2.2	
45	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. <i>Blood</i> , <b>2011</b> , 118, 3934-3934	2.2	
44	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenström Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2011</b> , 118, 2728-2728	2.2	
43	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. <i>Blood</i> , <b>2011</b> , 118, 2424-2424	2.2	
42	Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1033-41	12.9	105

41	Epigenetics in Waldenström's macroglobulinemia. <i>Epigenomics</i> , <b>2010</b> , 2, 691-6	4.4	2
40	Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. <i>Journal of Hematology and Oncology</i> , <b>2010</b> , 3, 38	22.4	12
39	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2010</b> , 115, 559-69	2.2	88
38	Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2010</b> , 115, 4051-60	2.2	69
37	microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2010</b> , 116, 1506-14	2.2	99
36	Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment. <i>Blood</i> , <b>2010</b> , 116, 142-142	2.2	2
35	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. <i>Blood</i> , <b>2010</b> , 116, 453-453	2.2	1
34	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. <i>Oncotarget</i> , <b>2010</b> , 1, 578-582	3.3	28
33	Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. <i>Oncotarget</i> , <b>2010</b> , 1, 578-82	3.3	16
32	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. <i>Blood</i> , <b>2010</b> , 116, 3622-3622		
31	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. <i>Blood</i> , <b>2010</b> , 116, 4035-4035	2.2	
30	Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells. <i>Blood</i> , <b>2010</b> , 116, 2958-2958	2.2	
29	LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 4914-4914	2.2	
28	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2010</b> , 116, 3620-3620		
27	Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. <i>Cancer Research</i> , <b>2009</b> , 69, 3579-88	10.1	128
26	Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6035-41	12.9	16
25	Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 250-5	2.2	129
24	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. <i>Blood</i> , <b>2009</b> , 113, 6669-80	2.2	265



23	Novel therapeutic agents in Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 84-6		4
22	Role of proteasome inhibition in Waldenström's macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , <b>2009</b> , 9, 94-6		3
21	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 626-34	2.2	20
20	microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 4391-402	2.2	98
19	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. <i>Blood</i> , <b>2009</b> , 113, 4341-51	2.2	354
18	RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. <i>Blood</i> , <b>2009</b> , 114, 619-29	2.2	94
17	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. <i>Blood</i> , <b>2009</b> , 114, 1785-1785	2.2	1
16	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2009</b> , 114, 3732-3732	2.2	2
15	Primary Waldenstrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. <i>Blood</i> , <b>2009</b> , 114, 3843-3843	2.2	
14	Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglobulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.. <i>Blood</i> , <b>2009</b> , 114, 2935-2935	2.2	
13	The Role of FGFR in the Progression of Waldenstrom's Macroglobulinemia and the Effect of Its Inhibition by TKI-258.. <i>Blood</i> , <b>2009</b> , 114, 3737-3737	2.2	
12	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2009</b> , 114, 4911-4911	2.2	
11	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2009</b> , 114, 4916-4916		
10	The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 775-85	4.5	18
9	SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 112, 150-8	2.2	104
8	Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1849-58	12.9	64
7	Targeting NF-kappaB in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 5068-77	2.2	92
6	Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 4752-63	2.2	69

5	MicroRNA Signature in Waldenstrom Macroglobulinemia. <i>Blood</i> , <b>2008</b> , 112, 630-630	2.2	2
4	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , <b>2007</b> , 110, 1516-1516	2.2	2
3	Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. <i>Blood</i> , <b>2007</b> , 110, 2512-2512	2.2	
2	The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2007</b> , 110, 2617-2617	2.2	
1	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom Macroglobulinemia.. <i>Blood</i> , <b>2007</b> , 110, 1383-1383	2.2	